Citadel Advisors
CMMB

Citadel Advisors’s Chemomab Therapeutics CMMB Stock Holding History

Citadel Advisors’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Buy
95,311
+31,129
+49% +$52.5K ﹤0.01% 12329
2026
Q1 		$101K Sell
64,182
-39,599
-38% -$67.7K ﹤0.01% 12015
2025
Q4 		$171K Buy
+103,781
New +$275K ﹤0.01% 11178
2024
Q3 		– Sell
-15,601
Closed -$57.4K – 14330
2024
Q2 		$57.4K Buy
+15,601
New +$54K ﹤0.01% 11604
2024
Q1 		– Sell
-8,169
Closed -$16.7K – 14645
2023
Q4 		$16.7K Buy
+8,169
New +$21.5K ﹤0.01% 12782
2022
Q4 		– Sell
-5,307
Closed -$53K – 14911
2022
Q3 		$53K Buy
+5,307
New +$68.4K ﹤0.01% 11581
2021
Q1 		– Sell
-190
Closed -$21K – 13211
2020
Q4 		$21K Buy
+190
New +$18.3K ﹤0.01% 10771

Other funds holding CMMB

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's CMMB Position: Q2 2026 in Review

Citadel Advisors increased its Chemomab Therapeutics (CMMB) stake by 49% in Q2 2026, buying an estimated $52.5K and bringing the position to 95,311 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #12329.

Citadel Advisors first reported a position in CMMB in Q4 2020 and has held it in 7 quarters since. The position peaked at $171K in Q4 2025. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • Citadel Advisors held 95,311 shares of Chemomab Therapeutics worth $154K as of Q2 2026.
  • Citadel Advisors bought 31,129 Chemomab Therapeutics shares in Q2 2026, an estimated $52.5K.
  • Chemomab Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12329 holding.
  • Citadel Advisors first reported a position in Chemomab Therapeutics in Q4 2020 and has held it in 7 quarters since.
  • Citadel Advisors's Chemomab Therapeutics position peaked at $171K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.